Abstract
Sphingolipid metabolites are critical to the regulation of a number of fundamental biological processes including cancer. Whereas ceramide and sphingosine mediate and trigger apoptosis or cell growth arrest, sphingosine 1- phosphate promotes proliferation, cell survival and angiogenesis. The delicate equilibrium between the intracellular levels of each of these sphingolipids is controlled by the enzymes that either produce or degrade these metabolites. Sphingosine kinase-1 is a crucial regulator of this two-pan balance, because it produces the pro-survival and pro-angiogenic sphingosine 1-phosphate and decreases the amount of both ceramide and sphingosine, the pro-apoptotic sphingolipids. Moreover, its gene is oncogenic, its mRNA is overproduced in several solid tumors, its overexpression protects cells from apoptosis, and its activity is down-regulated by anti-cancer treatments. Therefore, the sphingosine kinase-1/sphingosine 1-phosphate signaling pathway appears to be a target of interest for therapeutic manipulation.
Keywords: Antagonists, &, inhibitors, ceramide, sphingolipids, sphingosine, sphingosine kinase-1, sphingosine 1-phosphate, therapeutic antibody
Current Molecular Pharmacology
Title: Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Volume: 3
Author(s): Olivier Cuvillier, Isabelle Ader, Pierre Bouquerel, Leyre Brizuela, Bernard Malavaud, Catherine Mazerolles and Pascal Rischmann
Affiliation:
Keywords: Antagonists, &, inhibitors, ceramide, sphingolipids, sphingosine, sphingosine kinase-1, sphingosine 1-phosphate, therapeutic antibody
Abstract: Sphingolipid metabolites are critical to the regulation of a number of fundamental biological processes including cancer. Whereas ceramide and sphingosine mediate and trigger apoptosis or cell growth arrest, sphingosine 1- phosphate promotes proliferation, cell survival and angiogenesis. The delicate equilibrium between the intracellular levels of each of these sphingolipids is controlled by the enzymes that either produce or degrade these metabolites. Sphingosine kinase-1 is a crucial regulator of this two-pan balance, because it produces the pro-survival and pro-angiogenic sphingosine 1-phosphate and decreases the amount of both ceramide and sphingosine, the pro-apoptotic sphingolipids. Moreover, its gene is oncogenic, its mRNA is overproduced in several solid tumors, its overexpression protects cells from apoptosis, and its activity is down-regulated by anti-cancer treatments. Therefore, the sphingosine kinase-1/sphingosine 1-phosphate signaling pathway appears to be a target of interest for therapeutic manipulation.
Export Options
About this article
Cite this article as:
Cuvillier Olivier, Ader Isabelle, Bouquerel Pierre, Brizuela Leyre, Malavaud Bernard, Mazerolles Catherine and Rischmann Pascal, Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting, Current Molecular Pharmacology 2010; 3 (2) . https://dx.doi.org/10.2174/1874467211003020053
DOI https://dx.doi.org/10.2174/1874467211003020053 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Role of Natural Compounds Against Skin Aging
Current Medicinal Chemistry A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target
Current Cancer Drug Targets Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Telomeres and Thyroid Cancer
Current Genomics 3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors
Medicinal Chemistry Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Withdrawal Notice: Emerging Biomarkers and Contributing Factors of Prostate Cancer
Current Cancer Therapy Reviews Vesicovaginal Fistula
Current Women`s Health Reviews Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Enhanced Oral Bioavailability of Etodolac by the Liquisolid Compact Technique: Optimisation, In-Vitro and In-Vivo Evaluation
Current Drug Delivery Molecular Symmetry: A Structural Property Frequently Present in New Cytotoxic and Proapoptotic Drugs
Mini-Reviews in Medicinal Chemistry Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Neuronal Nicotinic Receptors as Brain Targets for Pharmacotherapy of Drug Addiction
CNS & Neurological Disorders - Drug Targets Current Concepts on the Management of Chordoma
Current Drug Therapy Candida Infections and Human Defensins
Protein & Peptide Letters Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics